Abstract:Background: Amyloid-beta (Abeta)-directed antibodies tested clinically for therapeutic activity against Alzheimer disease (AD) have shown varying degrees of efficacy. Although all of these antibodies target the Abeta peptide, their binding profile to different molecular species of Abeta differs and may underlie the observed variability in clinical outcomes. Objective: Explore the relationship between targeting of soluble toxic Abeta species and therapeutic efficacy. Methods: Surface plasmon resonance (SPR) was used to conduct a side-by-side comparison of the binding of various Abeta-directed antibodies to monomers and soluble Abeta oligomers from AD brains. Immunohistochemistry was performed to assess reactivity with plaque. Preclinical activity was assessed in human amyloid precursor protein (APP) transgenic mouse models of AD. Results: Non-selective, pan-Abeta reactive antibodies such as crenezumab and gantenerumab, which have failed to produce a clinical benefit, bound all forms of Abeta tested. In a competition assay, these antibodies lost the ability to bind toxic AD brain oligomers when exposed to monomers. Aggregate-selective antibodies such as aducanumab, lecanemab and donanemab, showed reduced monomer binding and a greater ability to withstand monomer competition which correlated with their reported inhibition of cognitive decline. Of the antibodies in earlier stages of clinical testing, ACU193 and PMN310 displayed the greatest ability to retain binding to toxic AD brain oligomers while PRX h2731 was highly susceptible to monomer competition. Plaque binding was observed with all aggregate-reactive antibodies with the exception of PMN310, which was strictly selective for soluble oligomers. Targeting of oligomers by PMN310 protected cognition and was not associated with microhemorrhages in mouse models of AD. Conclusions: Overall, these results suggest that selectivity for soluble toxic Abeta oligomers may be a driver of clinical efficacy, with a potentially reduced risk of ARIA if engagement with plaque is minimized.

In Search for Low-Molecular-Weight Ligands of Human Serum Albumin That Affect Its Affinity for Monomeric Amyloid β Peptide

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Multipronged Regulatory Functions of Serum Albumin in Early Stages of Amyloid-β Aggregation

Covalent immobilization of human serum albumin on cellulose acetate membrane for scavenging amyloid beta – A stepping extracorporeal strategy for ameliorating Alzheimer's disease

Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements

Inhibition of toxic metal-alpha synuclein interactions by human serum albumin

Alzheimer's Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2-7 Binding Affinity

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Computational Analysis for the Rational Design of Anti-Amyloid Beta (ABeta) Antibodies

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β

In vitro ADME, mouse pharmacokinetics of LD14b, and bioanalysis of a novel aβ 17β-HSD10 modulator for the treatment of Alzheimer's disease

Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrPC binding and downstream pathways

Computational Study of Natural Compounds for the Clearance of Amyloid-Βeta: A Potential Therapeutic Management Strategy for Alzheimer’s Disease

Inhibition of Amyloid Β Aggregation and Cytotoxicity by Berbamine Hydrochloride.

Altering plasma lipids and liver enzyme activities via hippocampal injections of hen Lysozyme amyloid aggregates in an Alzheimer's disease mouse model: Insights into the therapeutic role of Bis (Indolyl) phenylmethane

Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer’s disease

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non‐clinical species and Alzheimer's disease patients

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Structural Basis of the Drug-binding Specificity of Human Serum Albumin

Computational identification of promising therapeutics via BACE1 Targeting: Implications for Alzheimer's disease